Over 200 Companies Develop Next-Gen Drugs for Obesity Treatment

The obesity treatment field is rapidly advancing with over 200 companies developing more than 200 drugs in various stages of clinical trials. Leading pharmaceutical firms like Novo Nordisk and Eli Lilly are pioneering therapies including GLP-1 receptor agonists and multi-receptor agonists, with recent clinical successes and regulatory approvals highlighting the demand for effective and convenient obesity treatments. This growth in research and development corresponds with the increasing global prevalence of obesity and a shift toward pharmacologic management of the disease.

Originally published by gnews